Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Rollover Study
NCT02924272Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2016
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of ixazomib in multiple myeloma (MM), lymphoma and amyloidosis (2 arms), sponsored by Takeda. Primary endpoints: Serious Adverse Events up to 7 years, Adverse Events Grade 3 or Higher up to 7 years and 4 more. Started Dec 2016; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)lymphomaamyloidosis
Beyond the preview
Go deeper on NCT02924272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924272.